, Tracking Stock Market Picks
Enter Symbol:
Biomarin Pharmaceutical Inc. (BMRN) [hlAlert]

up 1,153.73 %

Biomarin Pharmaceutical Inc. (BMRN) rated Outperform with price target $21 by Leerink Swann

Posted on: Thursday,  Mar 12, 2009  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) on 03/12/2009, when the stock price was $10.44.
Since then, Biomarin Pharmaceutical Inc. has gained 1153.74% as of 11/25/2015's recent price of $130.89.
If you would have followed this Leerink Swann 's recommendation on BMRN, you would have gained 1153.73% of your investment in 2449 days.

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2009 8:25 AM Buy
10.44 21.00
as of 12/31/2009
1 Week up  35.18 %
1 Month up  54.75 %
3 Months up  41.31 %
1 YTD up  144.73 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy